

## In Silico Molecular Modeling of Chalcone Based Aryloxyethylamines as Antihyperglycemic Agents

Poonam Shukla<sup>1\*</sup>, Ram Pratap<sup>2</sup>, Shalini Singh<sup>3</sup>, Neha Rahuja<sup>4</sup>, Ashok K Prasad<sup>1</sup> and Arvind Kumar Shrivastava<sup>4</sup>

<sup>1</sup>Department of Chemistry, University of Delhi, Delhi, India

<sup>2</sup>Medicinal and Process Chemistry Division, Central Drug Research Institute, Lucknow, Uttar Pradesh, India

<sup>3</sup>QSAR and Cheminformatics Laboratory, Department of Chemistry, Bareilly College, Bareilly, Uttar Pradesh, India

<sup>4</sup>Department of Biochemistry, Central Drug Research Institute, Lucknow, Uttar Pradesh, India

### Abstract

Despite enormous efforts have been made in the search for new drugs, diabetes mellitus (DM) still remains the cause of mortality worldwide. A series of chalcone based aryloxyethylamines were synthesized and evaluated for their anti-hyperglycemic activity in SLM and STZ rat models. The majority of the compounds exhibited temperate to good activity ranging from 18.0% to 39.8% in SLM and 14.6% to 31.5% in STZ models, respectively. The most potent compound **31** exhibited glucose lowering of 27.0% in SLM and 31.5% in STZ models. A definite structure–activity relationship was observed while varying the nature and position of the different amines in ring-A of chalcone.

**Keywords:** Chalcone; Antihyperglycemic; Aryloxyethylamine; Oxidative stress; Antioxidant

### Introduction

Diabetes mellitus, an assembly of metabolic diseases in which the patient has elevated blood glucose, either because of insufficient insulin production or because the proper non-responsibility of body's cells to insulin, or both. NIDDM is a chaos characterized by insulin resistance, hyperglycemia and hyperinsulinaemia, frequently associated with obesity, dyslipidemia and hypertension foremost to cardiovascular risks [1]. In such cases, compensation of normal adipose tissue levels argues in mitigation of the insulin resistant state [2]. Diminution of body fat growth via diet and exercise is generally the first treatment for diabetes with the link between obesity and type-II diabetes. The anti-obesity drugs based therapies for NIDDM, are targeted at a lessening of energy intake or absorption (anorectic drugs) but an increase in energy expenditure (thermogenic drugs) serve as an gorgeous substitute for the treatment of obesity and hence, diabetes. Induction of thermogenesis is either through stimulation of nuclear receptor of PPAR family [3] or adrenergic receptor (AR) in membrane of adipose tissue [4].

In 1980s,  $\beta_3$ -adrenergic receptor was revealed on the cell surface of both white and brown adipose tissues.  $\beta_3$ -AR agonists were observed to concurrently augment lipolysis, fat oxidation, energy outlay [5] and insulin action foremost to the belief that, this receptor might afford as an attractive target for the treatment of diabetes and obesity [6]. Arylethanolamines and aryloxypropanolamines were first reported as  $\beta_3$ -AR agonists earlier [7]. CL-316,243 is the most selective  $\beta_3$ -AR agonist tested [8].

Troglitazone is also an antidiabetic drug of thiazolidinedione (**I**) class having unique structural feature [9], (Figure 1) is the presence of an antioxidant moiety of vitamin-E mutually with a PPAR- $\gamma$  nuclear receptor motivating pharmacophore in a single molecule. It is however failed with toxic metabolites but provided a source for further scheming molecules for multi-factorial diseases. Oxidative stress plays a vital role in diabetic patients by macrovascular complications through *Maillard reaction* [10]. The chalcones with antioxidant properties having plant origin have attracted our attention to explore hybrid structures with them for antidiabetic activity. Chalcones are natural products having various biological activities including antioxidant [11], antimalarial [12], antileishmanial [13], anti-inflammatory [14] and antitumor [15]. The antioxidative nature of chalcones might be one of the factors for different activities. In this ongoing programme, we have synthesized two series of chalcone based aryloxypropanolamines (**II**) [16] (Figure 1) have shown a potent anti-diabetic activity.




Figure 1: Prototypes of thiazolidinones and chalcones.





Figure 2: Prototype structure of synthesized molecules.



Scheme 1: Reagents: (i) Aq. NaOH, methanol, r. t., 6-8 hr; (ii) N, N-dialkylethylaminochloride, dried  $K_2CO_3$ , dry acetone.


















After biological evaluation of those molecules against diabetic rats and finding a potential activity, a different series of chalcone based molecules have been synthesized by replacing the CHO group from aryloxypropanolamine forming an aryloxyethylamines on ring-A of the basic moiety. The synthesized new prototype-III (Figure 2) have chalcone with pharmacophore which is used in different types of drugs as a side chain having property to increase lipophilicity. Most of the




**\*Corresponding author:** Poonam Shukla, Department of Chemistry, University of Delhi, Delhi, India, Tel: 7827963916; Fax: 7827963916; E-mail: [poonamshukla.du@gmail.com](mailto:poonamshukla.du@gmail.com)

Received July 22, 2017; Accepted July 28, 2017; Published July 31, 2017

**Citation:** Shukla P, Pratap R, Singh S, Rahuja N, Prasad AK, et al. (2017) In Silico Molecular Modeling of Chalcone Based Aryloxyethylamines as Antihyperglycemic Agents. Med Chem (Los Angeles) 7: 226-234. doi: [10.4172/2161-0444.1000461](https://doi.org/10.4172/2161-0444.1000461)

**Copyright:** © 2017 Shukla P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

| Compounds | Chemical Structure  | % Improvement SLM | % Lowering (STZ) |        |
|-----------|---|-------------------|------------------|--------|
|           |   |                   | 5 hr             | 24 hr  |
| 1         |    | +17.5             | ND               | ND     |
| 2         |    | 2.65              | ND               | ND     |
| 3         |    | 23.8*             | 5.63             | 17.6*  |
| 4         |    | 17.2              | ND               | ND     |
| 5         |    | 25.2*             | 11.7             | 14.0   |
| 6         |    | 11.3              | ND               | ND     |
| 7         |   | 21.3*             | 20.8**           | 18.0** |
| 8         |  | 18.8*             | 13.4             | 6.55   |
| 9         |  | 20.5*             | 14.8*            | 9.71   |
| 10        |  | 19.1*             | 11.0             | 12.2   |
| 11        |  | 18.0*             | 14.8*            | 20.4*  |
| 12        |  | 20.7*             | 21.9*            | 23.2*  |
| 13        |  | 25.8**            | 17.9*            | 16.0*  |
| 14        |  | 24.9**            | 27.6**           | 23.1** |
| 15        |  | 18.5*             | 15.0*            | 22.6*  |
| 16        |  | 22.8**            | 14.6*            | 14.3*  |
| 17        |  | 19.6*             | 29.4**           | 25.0** |

|    |   |         |         |        |
|----|---|---------|---------|--------|
| 18 |  | 19.0*   | 12.1    | 13.2   |
| 19 |  | 27.0**  | 31.5*** | 25.0** |
| 20 |  | 24.6**  | 17.1*   | 9.74   |
| SD | Metformin   | 35.6*** | 28.9**  | 25.7** |

**Table 1:** Effect of synthetic Compounds and standard drug metformin on glucose tolerance post sucrose load in normal rats and decline in blood glucose level in streptozotocin induced diabetic rats.

compounds of this new series have shown better anti-hyperglycemic activity than earlier series.

## Chemistry

### Synthesis of chalcone derived, ring-A substituted aryloxyethylamines (1-20)

The chalcones were synthesized with the help of Claisen-Schmidt condensation, which has been reported above. 4-hydroxy-acetophenone (A) and appropriate amount of substituted benzaldehydes (B<sub>1</sub>-B<sub>7</sub>) were reacted using aqueous sodium hydroxide in methanol at room temperature to provide corresponding hydroxy-chalcones (C<sub>1</sub>-C<sub>7</sub>). These chalcones were reacted with N, N-dialkylaminoethylchloride in presence of dried K<sub>2</sub>CO<sub>3</sub> (4-5eq.) in acetone to get products 1-20 (Scheme 1).

## Results and Discussion

### Anti-hyperglycemic activity of chalcone derived aryloxyethylamines

These molecules were evaluated for anti-hyperglycemic activity on both SLM and STZ models which have shown moderate to good potential as anti-hyperglycemic agents presented below (Table 1).

### Effect of compounds and standard drug metformin on improvement of glucose tolerance on normal rats (SLM)

A set of 20 substituted chalcones with different functionalities at R<sub>1</sub> and R<sub>2</sub> were synthesized in the Medicinal and Process Development Chemistry of the Institute. These were first evaluated for improvement in glucose tolerance in normal rats. The results obtained from the variance analysis showed in Table 1, depict the percentage improvement profile of 20 test compounds (1-20) and standard drug Metformin. Among these 20 compounds, most of the compounds i.e., 3, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 showed significant effect were calculated to be around 23.8, 25.2, 21.3, 18.8, 20.5, 19.1, 18.0, 20.7, 25.8, 24.9, 18.5, 22.8, 19.6, 19.0, 27.0 and 24.6% improvement in glucose tolerance respectively on blood glucose level of normoglycemic rats while the standard drug metformin treated group showed 35.6% improvement in SLM. The rest of the compounds did not cause any detectable improvement on the blood glucose level of normo-glycaemic rats.

### Effect of compounds and standard drug metformin on decline in blood glucose level of STZ treated diabetic rats

Those compounds which showed significant improvement in glucose tolerance in normal rats were further tested on low dosed Streptozotocin induced diabetic rats for their anti-hyperglycemic

activity evaluation. Among the tested compounds i.e., 3, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20, compound code 7, 9, 11, 12, 13, 14, 15, 16, 17, 19 and 20 caused significant decline of 20.8, 14.8, 14.8, 21.9, 17.9, 27.6, 15.0, 14.6, 29.4, 31.5, 17.1% during 5 hr and 18.0, 9.71, 20.4, 23.2, 16.0, 23.1, 22.6, 14.3, 25.0 25.0 and 9.74% during 24 hr respectively whereas Compound code 3, 5, 6, 8, 10 and 18 showed very mild effect on STZ treated rats. The standard drug Metformin at the dose level of 100 mg/kg showed a blood glucose lowering effect of 28.9% and 25.7% after 5 hr and 24 hr intervals respectively.

## Experimental Data

### Chemistry

**4<sup>2</sup>-(2-Dimethylamino-ethoxy)-3, 4-methelinedioxy-chalcone (1):** To a solution of 4-hydroxy-chalcone E<sub>1</sub> (0.5 g, 1.86 mmol) in dry acetone was added dried K<sub>2</sub>CO<sub>3</sub> (3eq.) of and 2-chloroethyl-dimethylamine (0.22 g, 2.14 mmol). This reaction mixture was refluxed for 7-8 hrs at 70°C to get 14. Solid, Yield: 27%, m. p.: 103°C, MS: 340 (M+1), IR(KBr): 3415, 1600, 449, <sup>1</sup>HNMR (300 MHz, CDCl<sub>3</sub>), δ 7.15 (d, J = 11.25 Hz, 2H 2', 6'-H), 7.73 (d, J = 15.51 Hz, 1H, β-H), 7.39 (d, J = 15.48 Hz, 1H, α-H), 7.17 (s, 1H, 2-H), 7.13 (d, J = 8.01 Hz, 1H, 6-H), 7.00 (d, J = 8.76 Hz, 2H, 3', 5'-H), 6.85 (d, J = 8.01 Hz, 1H, 5-H), 6.03 (s, 2H, OCH<sub>2</sub>O), 4.15 (t, 2H, OCH<sub>2</sub>), 2.769 (t, 2H, -NCH<sub>2</sub>), 1.62, (s, 6H, -NCH<sub>3</sub>).

**4<sup>2</sup>-(2-Diethylamino-ethoxy)-3, 4-methelinedioxy-chalcone (2):** To a solution of 4-hydroxy-chalcone E<sub>1</sub> (0.5 g, 1.86 mmol) in dry acetone was added dried K<sub>2</sub>CO<sub>3</sub> (5eq.) and 2-chloroethyl-diethylamine (0.25 g, 2.18 mmol). This reaction mixture was refluxed for 8-9 hrs at 70°C to get 15. Solid, Yield: 5%, m. p.: 105°C, MS: 368 (M+1), IR (KBr): 3020, 1516, 416, 767, <sup>1</sup>HNMR (200 MHz, CDCl<sub>3</sub>), δ 8.02 (d, J = 8.82 Hz, 2H 2', 6'-H), 7.73 (d, J = 15.52 Hz, 1H, β-H), 7.38 (d, J = 15.50 Hz, 1H, α-H), 7.17 (s, 1H, 2-H), 7.13 (d, J = 8.08 Hz, 1H, 6-H), 6.15 (d, J = 8.82 Hz, 2H, 3', 5'-H), 6.84 (d, J = 7.15 Hz, 1H, 5-H), 6.03 (s, 2H, OCH<sub>2</sub>O), 4.13 (t, 2H, OCH<sub>2</sub>), 2.7 (t, 2H, -NCH<sub>2</sub>), 2.27 (q, 4H, NCH<sub>2</sub>), 1.08 (t, 6H, CH<sub>3</sub>).

**4<sup>2</sup>-(2-Pyrrolidin-1-yl-ethoxy)-3, 4-methelinedioxy-chalcone (3):** To a solution of 4-hydroxy-chalcone E<sub>1</sub> (0.3 g, 1.12 mmol) in dry acetone was added dried K<sub>2</sub>CO<sub>3</sub> (4eq.) and 2-chloroethyl-pyrrolidine (0.15 g, 1.25 mmol). This reaction mixture was refluxed for 9-10 hrs at 70°C to get 16. Solid, Yield: 73.17%, m. p.: 140°C, MS (ESI): 366 (M+1), IR (KBr): 3380, 2361, 1515, 416, 670, <sup>1</sup>HNMR (300 MHz, CDCl<sub>3</sub>), δ 8.03 (d, J = 8.79 Hz, 2H 2', 6'-H), 7.74 (d, J = 15.54 Hz, 1H, β-H), 7.40 (d, J = 15.54 Hz, 1H, α-H), 7.19 (s, 1H, 2-H), 7.14 (d, J = 8.07 Hz, 1H, 6-H), 7.01 (d, J = 8.85 Hz, 2H, 3', 5'-H), 6.84 (d, J = 8.61 Hz, 1H, 5-H), 6.05 (s, 2H, OCH<sub>2</sub>O), 4.19 (t, 2H, OCH<sub>2</sub>), 2.11 (t, 2H, -NCH<sub>2</sub>), 2.67-2.27 (m, 4H, -NCH<sub>2</sub>), 1.87-1.82 (m, 4H, CH<sub>2</sub>-).

**4'-(2-Piperidin-1-yl-ethoxy)-3,4 methelinedioxy-chalcone (4):** To a solution of 4-hydroxy-chalcone E<sub>1</sub> (0.3 g, 1.12 mmol) in dry acetone was added dried K<sub>2</sub>CO<sub>3</sub> (4eq.) of and 2-chloroethyl-piperidine (0.47 g, 1.35 mmol). This reaction mixture was refluxed for 8-9 hrs at 70°C to get 17. Solid, Yield: 76.19%, m. p.: 42°C, MS (ESI): 380 (M+1), IR (KBr): 3380, 1516, 448, 668, <sup>1</sup>HNMR (300 MHz, CDCl<sub>3</sub>), δ 8.03 (d, J = 8.82 Hz, 2H 2', 6'-H), 7.74 (d, J = 15.51 Hz, 1H, β-H), 7.40 (d, J = 15.54 Hz, 1H, α-H), 7.19 (s, 1H, 2-H), 7.17 (d, J = 8.58 Hz, 1H, 6-H), 7.00 (d, J = 8.85 Hz, 2H, 3', 5'-H), 6.86 (d, J = 7.15 Hz, 1H, 5-H), 6.04 (s, 2H, OCH<sub>2</sub>O), 4.19 (t, 2H, OCH<sub>2</sub>), 2.82 (t, 2H, -NCH<sub>2</sub>), 2.56-2.52 (m, 4H, -NCH<sub>2</sub>), 1.66-1.60 (m, 6H, CH<sub>2</sub>).

**4'-(2-Azepan-1-yl-ethoxy)-3, 4-methelinedioxy-chalcone (5):** To a solution of 4-hydroxy-chalcone E<sub>1</sub> (0.3 g, 1.12 mmol) in dry acetone was added dried K<sub>2</sub>CO<sub>3</sub> (3eq.) and 2-chloroethyl-azepane (0.18 g, 1.25 mmol). This reaction mixture was refluxed for 7-8 hrs at 70°C to get 18. Solid, Yield: 7.8%, m. p.: 45°C, MS (ESI): 311 (M+1), IR (KBr): 3415, 290, 1515, 448, <sup>1</sup>HNMR (300 MHz, CDCl<sub>3</sub>), δ 8.02 (d, J = 8.84 Hz, 2H, 2', 6'-H), 7.73 (d, J = 15.50 Hz, 1H, β-H), 7.39 (d, J = 15.52 Hz, 1H, α-H), 7.17 (s, 1H, 2-H), 7.13 (d, J = 8.16 Hz, 1H, 6-H), 6.15 (d, J = 8.88 Hz, 2H, 3', 5'-H), 6.85 (d, J = 7.13 Hz, 1H, 5-H), 6.03 (s, 2H, OCH<sub>2</sub>O), 4.15 (t, 2H, OCH<sub>2</sub>), 2.15 (t, 2H, -NCH<sub>2</sub>), 2.79 (m, 4H, -NCH<sub>2</sub>), 1.27 (m, 8H, CH<sub>2</sub>).

**4'-(2-Morpholin-4-yl-ethoxy)-3, 4-methelinedioxy-chalcone (6):** To a solution of 4-hydroxy-chalcone E<sub>1</sub> (0.3 g, 1.12 mmol) in dry acetone was added dried K<sub>2</sub>CO<sub>3</sub> (5eq.) of and 2-chloroethyl-morpholine (0.168 g, 1.30 mmol). This reaction mixture was refluxed for 9-10 hrs at 70°C to get 19. Solid, Yield: 62.79%, m. p.: 135°C, MS (ESI): 382 (M+1), IR (KBr): 3378, 1515, 416, 670, <sup>1</sup>HNMR (300 M Hz, CDCl<sub>3</sub>), δ 8.04 (d, J = 8.85 Hz, 2H 2', 6'-H), 7.74 (d, J = 15.51 Hz, 1H, β-H), 7.40 (d, J = 15.48 Hz, 1H, α-H), 7.19 (s, 1H, 2-H), 7.17 (d, J = 8.43 Hz, 1H, 6-H), 7.00 (d, J = 8.79 Hz, 2H, 3', 5'-H), 6.9 (d, J = 8.82 Hz, 1H, 5-H), 6.05 (s, 2H, OCH<sub>2</sub>O), 4.20 (t, 2H, OCH<sub>2</sub>), 3.78-3.73 (m, 4H, -CH<sub>2</sub>OCH<sub>2</sub>), 2.85 (t, 2H, -NCH<sub>2</sub>), 2.63-2.58 (m, 4H, CH<sub>2</sub>NCH<sub>2</sub>).

**4'-(2-Diethylamino-ethoxy)-3, 5-dichloro-chalcone (7):** To a solution of 4-hydroxy-chalcone E<sub>2</sub> (0.5 g, 1.70 mmol) in dry acetone was added dried K<sub>2</sub>CO<sub>3</sub> (3eq.) of and 2-chloroethyl-diethylamine (0.24 g, 2.09 mmol). This reaction mixture was refluxed for 8-10 hrs at 70°C to get 40. Solid, Yield: 6.86%, m. p.: 105-106°C, MS (ESI): 39, 311 (M<sup>+</sup>, M<sup>+</sup>), IR (KBr): 3021, 1603, 416, 763, <sup>1</sup>HNMR (300 MHz, CDCl<sub>3</sub>), δ 8.02 (d, J = 8.82 Hz, 2H, 2', 6'-H), 6.16 (d, J = 8.82 Hz, 2H, 3', 5'-H), 7.5 (d, J = 1.53 Hz, 1H, 4-H), 7.68 (d, J = 15.69 Hz, 1H, β-H), 7.52 (d, J = 15.63 Hz, 1H, α-H), 7.50-7.43 (m, 2H, 2, 6-H), 4.13 (t, 2H, OCH<sub>2</sub>), 2.8 (t, 2H, NCH<sub>2</sub>), 2.27 (q, 4H, CH<sub>2</sub>), 1.08 (t, 6H, CH<sub>3</sub>).

**4'-(2-Piperidin-1-yl-ethoxy)-3, 5-dichloro-chalcone (8):** To a solution of 4-hydroxy-chalcone E<sub>2</sub> (0.5 g, 1.70 mmol) in dry acetone was added dried K<sub>2</sub>CO<sub>3</sub> (3eq.) and 2-chloroethyl-piperidine (0.260 g, 2.02 mmol). This reaction mixture was refluxed for 8-9 hrs at 70°C to get 21. Solid, Yield: 74.63%, m. p.: 107-27°C, MS (ESI): 404, 406 (M<sup>+</sup>, M<sup>+</sup>), IR (KBr): 3021, 1605, 416, 64, <sup>1</sup>HNMR (300 MHz, CDCl<sub>3</sub>), δ 8.02 (d, J = 8.88 Hz, 2H, 2', 6'-H), 6.16 (d, J = 8.85 Hz, 2H, 3', 5'-H), 7.5 (d, J = 1.68 Hz, 1H, 4-H), 7.68 (d, J = 15.69 Hz, 1H, β-H), 7.51 (d, J = 15.66 Hz, 1H, α-H), 7.47 (m, 2H, 2, 6-H), 4.19 (t, 2H, OCH<sub>2</sub>), 2.81 (t, 2H, NCH<sub>2</sub>), 2.52 (m, 4H, NCH<sub>2</sub>), 1.62 (m, 6H, CH<sub>2</sub>).

**4'-(2-Azepan-1-yl-ethoxy)-3, 5-dichloro-chalcone (9):** To a solution of 4-hydroxy-chalcone E<sub>2</sub> (0.5 g, 1.70 mmol) in dry acetone was added dried K<sub>2</sub>CO<sub>3</sub> (4eq.) and 2-chloroethyl-azepane (0.28 g, 1.85 mmol). This reaction mixture was refluxed for 8-9 hrs at 70°C to get 22. Solid, Yield: 6.86%, m. p.: 85-87°C, MS (ESI): 418, 420 (M<sup>+</sup>, M<sup>+</sup>), IR (KBr): 3021, 2359, 45, 64, <sup>1</sup>HNMR (200 MHz, CDCl<sub>3</sub>), δ 8.02 (d, J = 8.88

Hz, 2H, 2', 6'-H), 6.16 (d, J = 8.36 Hz, 2H, 3', 5'-H), 7.73 (s, 1H, 4-H), 7.69 (d, J = 15.82 Hz, 1H, β-H), 7.51 (d, J = 15.2 Hz, 1H, α-H), 7.52-7.46 (m, 2H, 2, 6-H), 4.15 (t, 2H, OCH<sub>2</sub>), 2.16 (t, 2H, NCH<sub>2</sub>), 2.79-2.76 (m, 4H, NCH<sub>2</sub>), 1.63 (s, 8H, CH<sub>2</sub>).

**4'-(2-Diethylamino-ethoxy)-4-chloro-chalcone (10):** To a solution of 4-hydroxy-chalcone E<sub>3</sub> (0.5 g, 1.10 mmol) in dry acetone was added of dried K<sub>2</sub>CO<sub>3</sub> (3eq.) and 2-chloroethyl-diethylamine (0.27 g, 2.19 mmol). This reaction mixture was refluxed for 8-9 hrs at 70°C to get 23. Solid, Yield: 78.57%, m. p.: 30-32°C, MS (ESI): 358 (M+1), IR (KBr): 3020, 1600, 417, 64, <sup>1</sup>HNMR (300 MHz, CDCl<sub>3</sub>), δ 8.02 (d, J = 8.82 Hz, 2H 2', 6'-H), 7.74 (d, J = 15.66 Hz, 1H, β-H), 7.57 (d, J = 8.49 Hz, 2H, 2, 6-H), 7.51 (d, J = 15.66 Hz, 1H, α-H), 7.39 (d, J = 8.46 Hz, 2H, 3, 5-H), 6.16 (d, J = 8.82 Hz, 2H, 3', 5'-H), 4.13 (t, 2H, OCH<sub>2</sub>), 2.7 (t, 2H, -NCH<sub>2</sub>), 2.27 (q, 4H, -NCH<sub>2</sub>), 1.08 (t, 6H, -CH<sub>3</sub>).

**4'-(2-Piperidin-1-yl-ethoxy)-4-chloro-chalcone (11):** To a solution of 4-hydroxy-chalcone E<sub>3</sub> (0.5 g, 1.10 mmol) in dry acetone was added dried K<sub>2</sub>CO<sub>3</sub> (5eq.) and 2-chloroethyl-piperidine (0.29 g, 2.24 mmol). This reaction mixture was refluxed for 8-9 hrs at 70°C to get 24. Solid, Yield: 88.23%, m. p.: 48-50°C, MS (ESI): 370 (M+1), IR (KBr): 3433, 1640, 64, <sup>1</sup>HNMR (300 M Hz, CDCl<sub>3</sub>), δ 8.04 (d, J = 8.85 Hz, 2H, 2', 6'-H), 7.77 (d, J = 15.66 Hz, 1H, β-H), 7.59 (d, J = 8.46 Hz, 2H, 2, 6-H), 7.53 (d, J = 15.63 Hz, 1H, α-H), 7.41 (d, J = 8.49 Hz, 2H, 3, 5-H), 7.01 (d, J = 8.88 Hz, 2H, 3', 5'-H), 4.22 (t, 2H, OCH<sub>2</sub>), 2.84 (t, 2H, -NCH<sub>2</sub>), 2.56-2.54 (m, 4H, -NCH<sub>2</sub>), 1.69-1.61 (m, 6H, -CH<sub>2</sub>).

**4'-(2-Azepan-1-yl-ethoxy)-4-chloro-chalcone (12):** To a solution of 4-hydroxy-chalcone E<sub>3</sub> (0.5 g, 1.10 mmol) in dry acetone was added dried K<sub>2</sub>CO<sub>3</sub> (4eq.) and 2-chloroethyl-azepane (0.32 g, 2.05 mmol). This reaction mixture was refluxed for 8-9 hrs at 70°C to get 25. Solid, Yield: 80.73%, m. p.: 28-30°C, MS (ESI): 384 (M+1), IR (KBr): 3450, 1608, 670, <sup>1</sup>HNMR (300 M Hz, CDCl<sub>3</sub>), δ 8.03 (d, J = 8.85 Hz, 2H 2', 6'-H), 7.76 (d, J = 15.60 Hz, 1H, β-H), 7.59 (d, J = 8.46 Hz, 2H, 2, 6-H), 7.53 (d, J = 5.5 Hz, 1H, α-H), 7.40 (d, J = 8.46 Hz, 2H, 3, 5-H), 7.01 (d, J = 8.85 Hz, 2H, 3', 5'-H), 4.19 (t, 2H, OCH<sub>2</sub>), 3.02 (t, 2H, -NCH<sub>2</sub>), 2.84-2.81 (m, 4H, -NCH<sub>2</sub>), 1.70-1.27 (m, 8H, -CH<sub>2</sub>).

**4'-(2-Diethylamino-ethoxy)-4-methyl-chalcone (13):** To a solution of 4-hydroxy-chalcone E<sub>4</sub> (0.5 g, 2.11 mmol) in dry acetone was added dried K<sub>2</sub>CO<sub>3</sub> (3eq.) and 2-chloroethyl-diethylamine (0.29 g, 2.25 mmol). This reaction mixture was refluxed for 8-9 hrs at 70°C to get 26. Liquid, Yield: 77.43%, MS (ESI): 338 (M+1), IR (Neat): 3414, 1605, 64, <sup>1</sup>HNMR (300 MHz, CDCl<sub>3</sub>), δ 8.04 (d, J = 8.79 Hz, 2H, 2', 6'-H), 7.81 (d, J = 15.63 Hz, 1H, β-H), 7.56 (d, J = 6.39 Hz, 2H, 2, 6-H), 7.52 (d, J = 13.15 Hz, 1H, α-H), 7.23 (d, J = 7.50 Hz, 2H, 3, 5-H), 6.16 (d, J = 8.79 Hz, 2H, 3', 5'-H), 4.16 (t, 2H, OCH<sub>2</sub>), 2.10 (t, 2H, CH<sub>2</sub>N), 2.70 (m, 4H, NCH<sub>2</sub>), 2.41 (s, 3H, CH<sub>3</sub>), 1.11 (t, 6H, CH<sub>3</sub>).

**4'-(2-Piperidin-1-yl-ethoxy)-4-methyl-chalcone (14):** To a solution of 4-hydroxy-chalcone E<sub>4</sub> (0.5 g, 2.11 mmol) in dry acetone was added dried K<sub>2</sub>CO<sub>3</sub> (4eq.) and 2-chloroethyl-piperidine (0.32g, 2.35mmol). This reaction mixture was refluxed for 8-9 hrs at 70°C to get 27. Solid, Yield: 84.10%, m. p.: 105-28°C, MS (ESI): 350 (M+1), IR (KBr): 3021, 1602, 64, <sup>1</sup>HNMR (300 MHz, CDCl<sub>3</sub>), δ 8.04 (d, J = 8.76 Hz, 2H, 2', 6'-H), 7.80 (d, J = 15.63 Hz, 1H, β-H), 7.56 (d, J = 8.49 Hz, 2H, 2, 6-H), 7.52 (d, J = 16.68 Hz, 1H, α-H), 7.24 (d, J = 7.6 Hz, 2H, 3, 5-H), 7.00 (d, J = 8.76 Hz, 2H, 3', 5'-H), 4.24 (t, 2H, OCH<sub>2</sub>), 2.87 (t, 2H, NCH<sub>2</sub>), 2.60 (s, 4H, NCH<sub>2</sub>), 2.41 (s, 3H, CH<sub>3</sub>), 1.69-1.27 (m, 6H, CH<sub>2</sub>).

**4'-(2-Azepan-1-yl-ethoxy)-4-methyl-chalcone (15):** To a solution of 4-hydroxy-chalcone E<sub>4</sub> (0.5 g, 2.11 mmol) in dry acetone was added dried K<sub>2</sub>CO<sub>3</sub> (5eq.) and 2-chloroethyl-azepane (0.35 g, 2.35 mmol). This reaction mixture was refluxed for 8-9 hrs at 70°C to get 28. Solid,

Yield: 78.74%, m. p.: 12-14°C, MS (ESI): 364 (M+1), IR (KBr): 3422, 473, 761, <sup>1</sup>HNMR (300MHz, CDCl<sub>3</sub>), δ 8.04 (d, J = 8.85 Hz, 2H, 2', 6'-H), 7.80 (d, J = 15.60 Hz, 1H, β-H), 7.56 (d, J = 8.34 Hz, 2H, 2, 6-H), 7.52 (d, J = 15.81 Hz, 1H, α-H), 7.24 (d, J = 7.9 Hz, 2H, 3, 5-H), 7.00 (d, J = 8.85 Hz, 2H, 3', 5'-H), 4.18 (t, 2H, OCH<sub>2</sub>), 3.01 (t, 2H, NCH<sub>2</sub>), 2.82 (m, 4H, NCH<sub>2</sub>), 2.41 (s, 3H, CH<sub>3</sub>), 1.69-1.27 (m, 8H, CH<sub>2</sub>).

**4'-(2-Diethylamino-ethoxy)-4-nitro-chalcone (16):** To a solution of 4-hydroxy-chalcone E<sub>5</sub> (0.5 g, 1.85 mmol) in dry acetone was added dried K<sub>2</sub>CO<sub>3</sub> (3eq.) and 2-chloroethyl-diethylamine (0.26 g, 2.32 mmol). This reaction mixture was refluxed for 8-9hrs at 70°C to get 29. Solid, Yield: 84.21%, m. p.: 32-34°C, MS (ESI): 369 (M+1), IR (KBr): 3440, 1660, 809, <sup>1</sup>HNMR (200 MHz, CDCl<sub>3</sub>), δ 8.28 (d, J = 8.76 Hz, 2H, 2, 6-H), 8.04 (d, J = 8.84 Hz, 2H 2', 6'-H), 7.82 (d, J = 15.84 Hz, 1H, β-H), 7.79 (d, J = 8.67 Hz, 2H, 2, 6-H), 7.27 (d, J = 15.68 Hz, 1H, α-H), 7.01 (d, J = 8.86 Hz, 2H, 3', 5'-H), 4.14 (t, 2H, OCH<sub>2</sub>), 2.8 (t, 2H, NCH<sub>2</sub>), 2.66 (q, 4H, -NCH<sub>2</sub>), 1.09 (t, 6H, -CH<sub>3</sub>).

**4'-(2-Piperidin-1-yl-ethoxy)-4-nitro-chalcone (17):** To a solution of 4-hydroxy-chalcone E<sub>5</sub> (0.5 g, 1.85 mmol) in dry acetone was added dried K<sub>2</sub>CO<sub>3</sub> (5eq.) and 2-chloroethyl-piperidine (0.28 g, 2.09 mmol). This reaction mixture was refluxed for 8-9 hrs at 70°C to get 30. Solid, Yield: 83.80%, m. p.: 42°C, MS (ESI): 381 (M+1), IR (KBr): 211, 1753, 74, 65, <sup>1</sup>HNMR (300 MHz, CDCl<sub>3</sub>), δ 8.29 (d, J = 8.76 Hz, 2H, 3, 5-H), 8.06 (d, J = 8.85 Hz, 2H 2', 6'-H), 7.83 (d, J = 15.69 Hz, 1H, β-H), 7.80 (d, J = 8.70 Hz, 2H, 2, 6-H), 7.67 (d, J = 15.5 Hz, 1H, α-H), 7.03 (d, J = 8.85 Hz, 2H, 3', 5'-H), 4.22 (t, 2H, OCH<sub>2</sub>), 2.83 (t, 2H, NCH<sub>2</sub>), 2.5423 (m, 4H, NCH<sub>2</sub>), 1.67-1.60 (m, 6H, CH<sub>2</sub>).

**4'-(2-Azepan-1-yl-ethoxy)-4-nitro-chalcone (18):** To a solution of 4-hydroxy-chalcone E<sub>5</sub> (0.5 g, 1.85 mmol) in dry acetone was added dried K<sub>2</sub>CO<sub>3</sub> (4eq.) and 2-chloroethyl-azepane (0.31 g, 2.26 mmol). This reaction mixture was refluxed for 8-9 hrs at 70°C to get 31. Solid, Yield: 82.19%, m. p.: 80-83°C, MS (ESI): 312 (M+1), IR (KBr): 3021, 1600, 64, <sup>1</sup>HNMR (200 MHz, CDCl<sub>3</sub>), δ 8.28 (d, J = 8.76 Hz, 2H, 3, 5-H), 8.04 (d, J = 8.82 Hz, 2H 2', 6'-H), 7.81 (d, J = 15.84 Hz, 1H, β-H), 7.78 (d, J = 8.68 Hz, 2H, 2, 6-H), 7.64 (d, J = 15.7 Hz, 1H, α-H), 7.01 (d, J = 8.82 Hz, 2H, 3', 5'-H), 4.19 (t, 2H, OCH<sub>2</sub>), 3.02 (t, 2H, NCH<sub>2</sub>), 2.83-2.80 (m, 4H, NCH<sub>2</sub>), 1.64 (s, 8H, CH<sub>2</sub>).

**4'-(2-Diethylamino-ethoxy)-2-chloro-chalcone (19):** To a solution of 4-hydroxy chalcone E<sub>6</sub> (0.5 g, 1.27 mmol) in dry acetone was added dried K<sub>2</sub>CO<sub>3</sub> (3eq.) and 2-chloroethyl-diethylamine (0.27 g, 2.40 mmol). This reaction mixture was refluxed for 8-9 hrs at 70°C to get 32. Liquid, Yield: 78.32%, MS (ESI): 358 (M+1), IR (Neat): 2139, 479, 761, <sup>1</sup>HNMR (300 MHz, CDCl<sub>3</sub>), δ 8.15 (d, J = 15.5 Hz, 1H, β-H), 8.02 (d, J = 8.85 Hz, 2H 2', 6'-H), 7.76-7.73 (m, 1H, 3-H), 7.49 (d, J = 15.5 Hz, 1H, α-H), 7.42 (m, 1H, 6-H), 7.33-7.30 (m, 2H, 4, 5-H), 6.16 (d, J = 8.85 Hz, 2H, 3', 5'-H), 4.13 (t, 2H, OCH<sub>2</sub>), 2.7 (t, 2H, -CH<sub>2</sub>N), 2.64 (q, 4H, -NCH<sub>2</sub>), 1.07 (t, 6H, -CH<sub>3</sub>).

**4'-(2-Piperidin-1-yl-ethoxy)-4-methoxy-chalcone (20):** To a solution of 4-hydroxy-chalcone E<sub>7</sub> (0.5 g, 1.13 mmol) in dry acetone was added dried K<sub>2</sub>CO<sub>3</sub> (4eq.) and 2-chloroethyl-piperidine (0.3 g, 2.19 mmol). This reaction mixture was refluxed for 8-9 hrs at 70°C to get 33. Liquid, Yield: 75.34%, MS (ESI): 366 (M+1), IR (Neat): 3418, 478, <sup>1</sup>HNMR (300 MHz, CDCl<sub>3</sub>), δ 7.80 (d, J = 15.66 Hz, 1H, β-H), 7.62 (d, J = 8.64 Hz, 2H 2', 6'-H), 7.40 (d, J = 15.63 Hz, 1H, α-H), 7.59-7.56 (m, 2H, 4, 6-H), 7.41 (s, 1H, 2-H), 7.14 (dd, J = 2.1, 8.07 Hz, 1H, 5-H), 6.13 (d, J = 8.76 Hz, 2H, 3', 5'-H), 4.20 (t, 2H, OCH<sub>2</sub>), 3.88 (s, 3H, OCH<sub>3</sub>), 2.82 (t, 2H, CH<sub>2</sub>N), 2.55 (m, 4H, NCH<sub>2</sub>), 1.27-1.60 (m, 4H, CH<sub>2</sub>), 1.51-1.45 (m, 2H, CH<sub>2</sub>).

## Biology

**Materials:** Streptozotocin and metformin were obtained from Sigma Chemical Company (St. Louis, USA). All the chemicals and reagents used were of analytical grade. Glucostrips were purchased from Roche Diagnostics, Germany.

**Animals:** 10 to 12 weeks old male albino rats of Sprague Dawley strain weighing around 140 ± 20 gm, procured from National Laboratory Animal Centre of CSIR-Central Drug Research Institute [CDRI], Lucknow, India. All procedures on these animals were conducted in strict accordance with the care and use of laboratory animals after getting the necessary approval by Institutional Animal Ethical Committee and were conducted in accordance with the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) formed by the Government of India in 1964. Animals were always placed in polypropylene cages in groups of five to six. The following norms were always followed for animal room environment: Temperature 23 ± 2°C; Humidity 50-60%; Light 300 Lux at floor level with regular 12 hr light cycle. The animals had always access to pellet diet and tap water unless stated otherwise.

**Improvement on glucose tolerance in normal rats (SLM):** The basal blood glucose level of each animal was measured by glucometer (Accucheck) after an overnight starvation. Animals showing fasting blood glucose level between 60 to 80 mg/dl were selected and divided into groups of five animals in each group. Rats of test groups were orally administered the suspension of the test sample prepared in 1.0% gum acacia at the dose of 100 mg/kg b.wt. and standard drug metformin at the dose of 100 mg/kg body wt. Animals of control group were given an equal amount of 1.0% gum acacia and termed as sham control. Oral loading of sucrose (10 g/kg b.wt.) was given to each animal after 30 min post administration of the test sample/vehicle. Blood glucose of each animal was again determined from the tail vein at 30, 60, 90 and 120 min post sucrose load by gluco-meter. Food but not water was withheld from the cages during the period of experimentation. Comparing the AUC of treated group with that of sham treated control group determined the percentage improvement on oral glucose tolerance post sucrose load by the test substance.

**Decline in blood glucose level of Streptozotocin-induced diabetic rats (STZ):** The fresh solution of STZ [60 mg/kg] in 100 mM citrate buffer, pH 4.5 was prepared and calculated amount of the fresh solution was immediately injected to overnight fasted rats intraperitoneally. Two days later baseline blood glucose was drawn from tail vein and glucose levels above 300 mg/dl were taken for the study and determined by glucostrips to confirm the induction of diabetes. Rats having hyperglycemia of the range of 300-400 mg/dl were considered diabetic, selected and were divided into groups of five animals each. One Group were used for normal control receives only vehicle [gum-acacia] and this group was termed as sham control. Other groups received the test samples and standard antidiabetic drugs at 100 mg/kg dose. The blood glucose was measured in blood sample obtained from tail vein at 30, 60, 90, 120, 180, 240, 300 and 1440 min post administration of test sample/vehicle. Food but not water was withheld from the cages upto 300 min period of experiment. The animals were allowed to feed over night to overcome drug induced hypoglycaemia after 300 min. The % decline in AUC of test samples or standard antidiabetic drug treated groups determined the % blood glucose lowering activity.

**Statistical analysis:** With the help of Area under curve (AUC) method (Prism Software), the quantitative glucose tolerance of every animal was calculated. The standard fall in AUC of experimental group compared to control group was always termed as % enhancement

on glucose tolerance or anti-hyperglycemic activity. The results are expressed as mean  $\pm$  SEM and statistical study was carried out to determine the level of significance by one-way ANOVA followed by Dunnett's test by graph pad prism software package. It is denoted by p values. Statistically significant differences were put at following levels \* represents  $p < 0.05$ , \*\* represents  $p < 0.01$ .

### Quantitative structure activity relationship

**The calibration set and the prediction set:** Chalcone based Aryloxyethylamines as Antihyperglycemic agents (Table 1) were included in the calibration set. The Antihyperglycemic activity was expressed by means of the equation  $A = -\log(\text{activity})$ . In this mentioned study it has been also observed that A series of chalcone aryloxyethylamines of type 1-16 (Table 1) act as their anti-hyperglycemic activity, with variable efficacies, depending on their chemical structure. The prediction set contains 13 other not yet synthesized substituted of chalcone aryloxyethylamines, having unknown observed values of activity (Table 1) and structure presented in Figure 2. The discovery of novel bioactive molecule is the primary goal of computational drug discovery. The discovery of novel bioactive molecule is the primary goal of computational drug discovery. The virtual constructions of the molecules and geometry optimization have been done using the Molecular Mechanics force field MM<sup>+</sup> of Hyper Chem software [17] (version 7.52, HyperCube Inc. Florida USA). The MM+ force field is an extension of latest MM2 force field which was developed by Allinger and co-workers [18,19]. Separately, for each molecule, 3224DRAGON [20] (version 5.5, Talete srl, Milano, Italy) descriptors have been calculated. Several criteria were used to reduce the DRAGON descriptors while optimizing the information content of the descriptors set. First, descriptors for which no value was available for all the compounds were disregarded. Second, descriptors of which the value is constant (or near-constant) inside each group of descriptors were excluded. After these automatic screening procedures, a set of 1598 DRAGON descriptors was obtained for further analysis. The statistical calculations used for obtaining the QSAR equations were done with PRECLAV as reported earlier [21-23].

**Descriptor calculation and quality of the model:** The program PRECLAV (8.) computes type (2) multilinear QSARs.

$$A = C_0 + \sum_{i=1}^k C_i \cdot D_i \quad (1)$$

where, A is (the value of) activity;  $C_0$  is the free term intercept);  $C_i$  are coefficients (weighting factors);  $D_i$  are (the value of) significant descriptors; k is the number of descriptors.

The square of Pearson linear correlation  $r^2$  of observed/computed values, the Fisher function F, the standard error of estimation SEE, and the quality function  $Q^1$  are criteria for the quality of prediction for the molecules in calibration set.

$$F = r^2 / (1 - r^2) \cdot (N - p) / p \quad (2)$$

$$SEE = [(\sum \Delta^2) / (N - 1)]^{1/2} \quad (3)$$

$$Q = r^2 \cdot (1 - p / N) \quad (4)$$

where: p is number of descriptors; N is number of molecules in the calibration set;  $\Delta$  is difference  $A_{\text{obs}} - A_{\text{calc}}$ . The descriptors included in the best (by Q function) QSAR are named 'predictors'. The relative utility of predictors is computed by the formula (6).

$$U = (R^2 - r^2) / (1 - r^2) \quad (5)$$

where  $R^2$  is the square of Pearson correlation between the observed

values and the computed values (using p predictors)  $r^2$  is the square of Pearson correlation between the observed values and the calculated values (using the p-1 predictors, i.e., the QSAR equation without the analyzed predictor)

After computation of  $U^{24}$  for each predictor, the values of U are normalized by the highest of them (the highest value for U becomes 1000). The predictors with high enough value of U ( $U > 500$ ) can be considered 'with high relative utility'. These predictors are useful because they correlate well with  $A_{\text{obs}}$  values and present low correlation with other descriptors.

PRECLAV [24] calculates square of cross-validated correlation  $r_{\text{CV}}^2$  using LHO (Leave Half Out) method. However, this usual method is applied after ordering of molecules in calibration set according to the observed values of activity. Therefore, the cross-validated function  $r_{\text{CV}}^2$  is a measure of homogeneity of calibration set from the point of view of predictors' set, i.e., from the point of view of structure-activity relationship. A low value ( $< 0.4$ ) of  $r_{\text{CV}}^2$  means 'the QSAR for molecules having high values of activity and the QSAR for molecules having low values of activity include the same descriptors, but very different weighting factors'. Actually, the computation of  $r_{\text{CV}}^2$  is a very drastic 'internal validation test'.

**Applicability of domain and detection of outliers:** A QSAR model can be used for showing new compounds if its domain of application is defined [25,26]. The need to characterize the model applicability domain is also reflected in the OECD guiding principle for QSAR model validation [27,28]. QSAR model should only be used for making predictions of compounds fall within the specified domain may be considered reliable. Extent of extrapolation [29,30] is one simple approach to define the applicability of the domain. It is based on the calculation of the hat diagonal (leverage)  $h_i$  for each chemical, where the QSAR model is used to predict its activity.

$$h_i = \frac{1}{2} \mathbf{x}_i^T (\mathbf{X}^T \mathbf{X})^{-1} \mathbf{x}_i \quad (8)$$

In equation 9,  $\mathbf{x}_i$  is the descriptor-row vector of the query molecule and X is the  $k \times n$  matrix containing the k descriptor values for each one of the n training molecules. A hat diagonal (leverage) value  $> 3(k+1)/n$  leverage warning limit is considered large.

Outliers are compounds that are poorly fit by the regression model. Outlying compounds should not be removed unless a good reason for their removal can be given. The variance of the observed residuals is not constant. This makes comparisons among the residuals difficult. One solution is to standardize the residuals [31,32], by dividing by their standard deviations. This gives a set of standardized residuals. The cross-validated LOO standardized residuals is a  $|RStudent|$  that has the impact of a single observation removed from the mean square error. A molecule is defined as an outlier in which  $|RStudent| > 2$  [32-34].

To visualize the applicability of domain of a developed QSAR model, William plot was used. In the William plot,  $|RStudent|$  versus leverage values ( $h_i$ ) are plotted. This plot could be used for an immediate and simple graphical detection of both the response outliers and structurally influential compounds in a model. It must be noted that compounds with high value of leverage and good fitting in the developed model can stabilize the model. On the other hand, compounds with bad fitting in the developed model may be outliers. Thus, combination of leverage and the  $|RStudent|$  could be used for assigning the applicability of domain [35-37].

### Results and Discussion

The statistical computations were conducted using the specific

formulas and procedures of PRECLAV program algorithm. Using only the “significant” descriptors, PRECLAV computes ten thousand QSAR type (3) multilinear equations. The quality of the obtained equation is reflected by the value of the Q function and also by values of some usual statistical functions. During the PRECLAV MLR analysis using Dragon descriptor, we observed that the 3-parametric model has the highest value of the Q function for anti-hyperglycemic activity and also has the highest predictive power as follows:

Dependent property: antihyperglycemic activity (A)

Molecules number in calibration set: 16

Number of “significant” descriptors in presence of set: 277

$A = 4.3733 - 1.0262 (\text{Eig06\_A}) + 6.3981 (\text{G2p}) - 7.057 (\text{G2m})$

Eig06\_A = eigen value n. 6 from augmented edge adjacency mat. weighted by edge degree Edge adjacency indices Eigenvalues (U=1000)

G2p=2nd component symmetry directional WHIM index / weighted by polarizability (U=829)

G2m=2nd component symmetry directional WHIM index / weighted by mass WHIM descriptors Directional descriptors (U= 912), SEE = 0.0466;  $r_2 = 0.925$ ;  $F = 53.4748$ ;  $r_2, cv = 0.8777$ ,  $r_{pred^2} = 0.85599$ . SEE = Standard Error of Estimation,  $r_2$  = Pearson square correlation,  $F$  = Fisher function,  $r_2cv$  = Pearson cross validated square correlation (Leave one out method),  $r_{pred^2}$  = predictive  $r_2$  According to algebraic sign of coefficients in QSAR formula and the value of utility U the main factor in influence on activity value is the Eigenvalues [Eigenvalues of the edge adjacency matrix (Eigk\_EA), augmented edge adjacency matrices (Eigk\_AEA(w) and unsymmetrical weighted edge adjacency matrices (Eigk\_EA(w)) are also provided by Dragon and Directional WHIM descriptors [WHIM descriptors (*Weighted Holistic Invariant Molecular descriptors*) are geometrical descriptors based on statistical indices calculated on the projections of the atoms along principal axes.

WHIM descriptors are built in such a way as to capture relevant molecular 3D information regarding molecular size, shape, symmetry and atom distribution with respect to invariant reference frames) Play dominant role in activity. The negative correlation of Eig06A shows that, increases this descriptor value decreases the activity and positive correlation of the G2p shows the increase the polarizability increase the activity.


### Validation of the computation procedure

For the validation of the method, we have proceeded to a QSAR study with a validation set and reduced calibration set. The set in bold letter with star containing compound in Table 1 are the most significant is the correlation between the calculated and selected for validation set (comp. no 2,10,12 and 16). The selection of the validation set should be such that it captures all the features and characteristics of the whole set of molecules validation set was extracted from the homogenized calibration. From the point of view of them considerations discussed here, the experimental values of activity for the molecules in the validation set. In Table 2 and Figure 1 there are listed the calculated values and the experimental values of the anti-hyperglycemic activity power for the molecules in the validation set. We have found good predictive  $r^2$ .


**Applicability domain:** We used |RStudent| of observed inhibitory activity calculated by the obtained models and hat diagonal (leverage) for assigning applicability of domain (AD). Values for leverage have been calculated for both calibration set and prediction set compounds showing in Table 2. Applicability of domain for the developed model

| Comp. No. | (A) Obs. | (A)Est. | Res.   | R Student | Diagonal | Comp. No. | A (predicted Value) |
|-----------|----------|---------|--------|-----------|----------|-----------|---------------------|
| 3         | 1.2455   | 1.193   | 0.053  | 1.0871    | 0.1133   | A         | 3.001               |
| 5*        | 1.1461   | 1.12    | 0.026  | 0.5578    | 0.2245   | B         | 2.683               |
| 7         | 1.2553   | 1.305   | -0.05  | -1.031    | 0.1304   | C         | 2.734               |
| 8         | 0.8162   | 0.858   | -0.042 | -1.0729   | 0.428    | D         | 2.765               |
| 9         | 0.9872   | 0.952   | 0.035  | 0.8383    | 0.3809   | E         | 2.422               |
| 10        | 1.0864   | 1.136   | -0.049 | -1.1263   | 0.2783   | F         | 2.53                |
| 11        | 1.3096   | 1.357   | -0.047 | -1.0226   | 0.2083   | G         | 2.045               |
| 12        | 1.3655   | 1.288   | 0.078  | 1.669     | 0.0845   | H         | 2.692               |
| 13        | 1.2041   | 1.239   | -0.035 | -0.6915   | 0.0973   | I         | 2.052               |
| 14*       | 1.3636   | 1.3     | 0.063  | 1.3873    | 0.1713   | J         | 2.689               |
| 15        | 1.3541   | 1.397   | -0.043 | -0.9113   | 0.1776   | K         | 2.283               |
| 16*       | 1.1553   | 1.113   | 0.042  | 0.8367    | 0.0923   | L         | 2.395               |
| 17        | 1.3979   | 1.372   | 0.026  | 0.8189    | 0.6436   | M         | 1.835               |
| 18        | 1.1206   | 1.178   | -0.058 | -1.2749   | 0.205    | -         | -                   |
| 19        | 1.3979   | 1.395   | 0.003  | 0.0707    | 0.2451   | -         | -                   |
| 20*       | 0.9886   | 0.99    | -0.002 | -0.0437   | 0.5196   | -         | -                   |

**Table 2:** Observed anti-hyperglycemic activity and their corresponding A value where A=-log. anti-hyperglycemic activity, estimated inhibition constant (A), hat diagonal, standardized residual, |RStudent| of the calibration set molecules of chalcone having good % lowering in STZ (24 hrs) model and predicted value of A-M not yet synthesized compounds.



**Figure 3:** Effect of synthetic compounds and standard antidiabetic drug metformin on blood glucose profile of streptozotocin-induced diabetic rats. Values are mean % change in 5 animals of a group; significance: \* $p < 0.05$ , \*\* $p < 0.01$  when compared with control.



**Figure 4:** Structure of compounds A-M predicted as antihyperglycemic agents.




Figure 5: Observed versus estimated inhibitory activity (A) of Calibration set.




Figure 6: Observed versus estimated inhibitory activity (A) of training set and test set.




Figure 7: |RStudent| of observed vs. Hat Diagonal.

of calibration set is shown in William plot (Figures 3-7). Influential compounds are points with leverage value higher than the warning leverage limit 1, so outliers are not present. It can be seen in the William plot; all molecules in calibration set lie in the application domain of the developed model. The computed activity of the prediction set compounds is also within limit of hat diagonal.

## Conclusions

The compounds with alkylaminoethoxy group on ring-A and electron withdrawing group on ring-B exhibited potential antihyperglycemic activity in SLM and STZ models. In calibration set polarizibility and Mass play dominant role for the activity. Many molecules in proposed prediction set have much higher computed activity than observed value and their hat diagonal within limit. Thus, attempts have been made to design and develop novel drugs against antihyperglycemic activity on a rational basis so as to decrease the test and fault issue and predict the biological activity before synthesis.

## Acknowledgements

Authors are grateful to Director, CDRI, Lucknow, India, for constant encouragement of the drug development program for metabolic diseases and Sophisticated Analytical Instrumentation Facility (SAIF) group for spectral data. Poonam is grateful to UGC, New Delhi, for awarding Junior Research Fellowship and University of Delhi for other support.

## References

- Ginsberg H, Plutzky J, Sobel BE (1999) A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering. *Journal of cardiovascular risk* 6: 337-346.
- Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, et al. (2000) Surgical implantation of adipose tissue reverses diabetes in lipotrophic mice. *Journal of Clinical Investigation* 105: 271.
- Murphy JE, Zhou S, Giese K, Williams LT, Escobedo JA, et al. (1997) Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin. *Proceedings of the National Academy of Sciences* 94: 13921-13926.
- Nourparvar A, Bulotta A, Di Mario U, Perfetti R (2004) Novel strategies for the pharmacological management of type 2 diabetes. *Trends in pharmacological sciences* 25: 86-91.
- Arch JR, Ainsworth AT (1983) Thermogenic and antiobesity activity of a novel beta-adrenoceptor agonist (BRL 26830A) in mice and rats. *The American journal of clinical nutrition* 38: 549-558.
- Holloway BR, Howe R, Rao BS, Stribling D (1992) ICI D7114: a novel selective adrenoceptor agonist of brown fat and thermogenesis. *The American journal of clinical nutrition* 55: 262S-264S.
- Goldberg DE, Frishman WH (1995) *b3-Adrenergic Agonism: A New Concept in Human Pharmacotherapy*, Futura publishing Co. Armonk: New York.
- Leo A, Muller M (1986) *Eur. Patent EP 14023, 1985. InChem. Abstr* 104: 68565.
- Shukla P, Singh AB, Srivastava AK, Pratap R (2007) Chalcone based aryloxypropanolamines as potential antihyperglycemic agents. *Bioorganic & medicinal chemistry letters* 17: 799-802.
- Bloom JD, Dutia MD, Johnson BD, Wissner A, Burns MG, et al. (1992) Disodium (R, R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl] amino] propyl]-1, 3-benzodioxole-2, 2-dicarboxylate (CL 316,243). A potent. beta.-adrenergic agonist virtually specific for. beta. 3 receptors. A promising antidiabetic and antiobesity agent. *Journal of medicinal chemistry* 35: 3081-3084.
- Oguchi M, Wada K, Honma H, Tanaka A, Kaneko T, et al. (2000) Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2, 4-diones. *Journal of medicinal chemistry* 43: 3052-3066.
- Monnier VM (1989) Toward a Maillard reaction theory of aging. *Progress in clinical and biological research* 304: 1-22.
- Vaya J, Belinky PA, Aviram M (1997) Antioxidant constituents from licorice roots: isolation, structure elucidation and antioxidative capacity toward LDL oxidation. *Free Radical Biology and Medicine* 23: 302-313.
- Chen M, Christensen SB, Zhai L, Rasmussen MH, Theander TG, et al. (1997) The novel oxygenated chalcone, 2, 4-dimethoxy-4'-butoxychalcone, exhibits potent activity against human malaria parasite *Plasmodium falciparum* in vitro and rodent parasites *Plasmodium berghei* and *Plasmodium yoelii* in vivo. *Journal of Infectious Diseases* 176: 1327-1333.
- Nielsen SF, Christensen SB, Cruciani G, Kharazmi A, Liljefors T (1998) Antileishmanial chalcones: Statistical design, synthesis, and three-dimensional quantitative structure- activity relationship analysis. *Journal of Medicinal Chemistry* 41: 4819-4832.
- Hsieh HK, Lee TH, Wang JP, Wang JJ, Lin CN (1998) Synthesis and anti-inflammatory effect of chalcones and related compounds. *Pharmaceutical research* 15: 39-46.
- Kumar SK, Hager E, Pettit C, Gurulingappa H, Davidson NE, et al. (2003) Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. *Journal of medicinal chemistry* 46: 2813-2815.
- Shukla P, Singh AB, Srivastava AK, Pratap R (2007) Chalcone based aryloxypropanolamines as potential antihyperglycemic agents. *Bioorganic & medicinal chemistry letters* 17: 799-802.
- Satyanarayana M, Tiwari P, Tripathi BK, Srivastava AK, Pratap R (2004) Synthesis and antihyperglycemic activity of chalcone based aryloxypropanolamines. *Bioorganic & medicinal chemistry* 12: 883-889.
- Shukla P, Singh AB, Srivastava AK, Pratap R (2007) Chalcone based aryloxypropanolamines as potential antihyperglycemic agents. *Bioorganic & medicinal chemistry letters* 17: 799-802.
- Hyper Chem Software 7.52 (2006) Hyper Cube Inc. Florida Science and Technology Park, 1115, NW. 4<sup>th</sup> street Gainesville Florida, 326001, USA.



22. Allinger NL (1977) Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms. *Journal of the American Chemical Society* 99: 8127-8134.
23. Allinger NL, Yuh YH (1982) Quantam chemistry program exchange, Bloomington, Indiana Program No. 395. In: *Molecular Mechanics*. Burkert U, Allinger NL (eds.), ACS Monograph 177, Washington DC, USA.
24. Talete srl (2007) DRAGON Plus for windos software for molecular descriptor calculations version 5.5, Milano, Italy.
25. Laszlo T (2007) QSAR studies regarding the inhibition of the carbonic anhydrase by the sulfonamides containing a picolinoyl group. *Revista De Chimie* 58: 191-194.
26. Singh S (2009) Comparative QSAR studies on the novel series of thiazolones and tetrazole derivatives as HCV NS5B polymerase allosteric inhibitors. *Lett. Drug Des. Discov* 6: 286-297.
27. Singh S, Singh S, Shukla P (2010) Modeling of novel HIV-1 protease inhibitors incorporating N- Aryl-oxazolidinone-5-carboxamides as P2 ligands using quantum chemical and topological finger print descriptors. *Med. Chem. Res* 20: 1556-1565.
28. PRECLAV and DESCRIPT programmes are available from Center of Organic Chemistry Bucharest–Romanian Academy.
29. Golbraikh A, Tropsha A (2002) Beware of q 2!. *Journal of molecular graphics and modelling* 20: 269-276.
30. Osten DW (1988) Selection of optimal regression models via cross-validation. *Journal of Chemometrics* 2: 39-48.
31. OECD (2007) Organization for Economic Co-operation and Development Guidance Document on the Validation of (Quantitative) Structure-Activity Relationship QSAR Models. OECD Document ENV/JM/ MONO.
32. Netzeva TI, Worth AP, Aldenberg T, Benigni R, Cronin MT, et al. (2005) Current status of methods for defining the applicability domain of (quantitative) structure-activity relationships. *ATLA* 33: 155-173.
33. Tropsha A, Gramatica P, Gombar VK (2003) The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. *Molecular Informatics* 22: 69-77.
34. Weaver S, Gleeson MP (2008) The importance of the domain of applicability in QSAR modeling. *Journal of Molecular Graphics and Modelling* 26: 1315-1326.
35. NCSS (2004) Statistical Software Delux package, 329 North 1000 East, Kaysville, UT, USA.
36. Dennis RC (1982) *Residuals and Influence in Regression*. New York: Chapman, Todeschini HR, Lasagni M, Marengo E, J. *Chemom.* 8: 263-273.
37. Todeschini R, Gramatica P (1998) *3D QSAR in Drug Design*. Kubinyi H, Folkers G, Martin YC, Kluwer/ESCOM, Dordrecht, The Netherlands 355-380.

**Citation:** Shukla P, Pratap R, Singh S, Rahuja N, Prasad AK, et al. (2017) *In Silico* Molecular Modeling of Chalcone Based Aryloxyethylamines as Antihyperglycemic Agents. *Med Chem (Los Angeles)* 7: 226-234. doi: [10.4172/2161-0444.1000461](https://doi.org/10.4172/2161-0444.1000461)

### OMICS International: Open Access Publication Benefits & Features

#### Unique features:

- Increased global visibility of articles through worldwide distribution and indexing
- Showcasing recent research output in a timely and updated manner
- Special issues on the current trends of scientific research

#### Special features:

- 700+ Open Access Journals
- 50,000+ editorial team
- Rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at major indexing services
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: <http://www.omicsonline.org/submission>